Physician profile
Stephen Scarantino
NPI 1316938921
$14,890.70
in general payments reported to CMS, 2019-2025
26 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $400 · 2021: $187 · 2022: $334 · 2023: $2,854 · 2024: $9,209 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,077 · Travel and Lodging: $3,526 · Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,076.82 |
| Travel and Lodging | $3,526.17 |
| Food and Beverage | $2,775.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,931.82 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $560.02 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $497.73 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $349.22 | 2023 | Ova1 |
| Celularity INC. | $300.00 | 2020 | |
| Mayne Pharma Commercial LLC | $280.09 | 2022-2025 | |
| Astellas Pharma US INC | $210.94 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $191.91 | 2023-2025 | Accrufer |
| Pfizer INC. | $164.26 | 2021-2024 | |
| Hologic Sales and Service, LLC | $161.45 | 2020-2025 | Fluent Fluid Management System, Thinprep 2000 Processor |
| Amag Pharmaceuticals, INC. | $145.54 | 2019-2020 | |
| Myovant Sciences INC. | $139.43 | 2021-2022 | |
| Novo Nordisk INC | $139.17 | 2023 | Wegovy |
| Exeltis, USA INC. | $122.59 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $108.63 | 2023-2024 | Twirla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $95.03 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $87.64 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $87.42 | 2019-2025 | |
| Lupin INC. | $81.83 | 2019 | |
| Organon LLC | $45.51 | 2022-2023 | Nexplanon |
| Therapeuticsmd, INC. | $44.79 | 2019 | |
| Allergan, INC. | $42.31 | 2019-2020 | |
| Evofem Biosciences, INC. | $35.17 | 2024-2025 | Solosec, Phexx, Phexxi |
| Roche Diagnostics Corporation | $32.41 | 2019 | |
| Duchesnay USA Incorporated | $23.57 | 2019 | |
| Avion Pharmaceuticals | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Scarantino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.